Antion Biosciences SA announced that it will receive a preferred equity round of funding on January 11, 2022. The transaction will include participation from new investor Allogene Therapeutics, Inc. As part of the transaction, Allogene Therapeutics, Inc. will take a seat on board of directors of the company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.885 USD | -5.10% | -16.62% | -10.12% |
Mar. 18 | Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index | CI |
Mar. 15 | Allogene Therapeutics Files $500 Million Mixed Shelf | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.12% | 519M | |
-2.77% | 104B | |
+0.74% | 97.42B | |
+1.37% | 22.2B | |
-18.07% | 21.23B | |
-10.67% | 18.33B | |
-42.33% | 16.35B | |
-18.11% | 15.06B | |
+5.04% | 13.98B | |
+27.88% | 11.66B |
- Stock Market
- Equities
- ALLO Stock
- News Allogene Therapeutics, Inc.
- Antion Biosciences SA announced that it expects to receive funding from Allogene Therapeutics, Inc.